On Friday, Incyte Corporation (NASDAQ:INCY) released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL). The study enrolled 654 adults. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment in follicular lymphoma. Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication. It also met key secondary endpoints of ...